GlassScriptPhysician profile
Oleg Lisitsyn
NPI 1811948052
$3,680.24
in general payments reported to CMS, 2019-2025
18 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $66.23 · 2021: $550 · 2022: $376 · 2023: $686 · 2024: $582 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $618.80 | 2021-2025 | Cequa |
| Biotissue Holdings INC. | $516.13 | 2021-2025 | |
| Alcon Vision LLC | $465.06 | 2022-2025 | Eysuvis, Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $453.96 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $432.24 | 2019-2023 | |
| Allergan, INC. | $276.63 | 2019-2021 | |
| Shire North American Group INC | $185.40 | 2019 | |
| Oyster Point Pharma, INC. | $154.70 | 2022-2025 | Tyrvaya |
| Amgen INC. | $108.01 | 2024-2025 | Tepezza |
| Coopervision INC. | $86.51 | 2024 | Paragon Crt |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.87 | 2019-2020 | |
| Dompe US, INC. | $74.88 | 2025 | Oxervate |
| Harrow Eye, LLC | $50.57 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $49.11 | 2021-2022 | |
| Abbvie INC. | $45.65 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $37.55 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $24.38 | 2021 | |
| Horizon Therapeutics Plc | $20.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleg Lisitsyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.